Michael Kelliher
Director/Board Member at CAPRICOR THERAPEUTICS, INC.
Net worth: 1 M $ as of 29/04/2024
Profile
Michael Kelliher is currently an Independent Director at Capricor Therapeutics, Inc. since 2023 and an Executive VP-Corporate Development & Strategy at Ardelyx, Inc. since 2024.
Previously, he worked as a Group Vice President-Merger & Acquisition at Horizon Therapeutics Plc.
He completed his undergraduate degree at University College Cork.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARDELYX, INC.
0.07% | 24/03/2024 | 160,000 ( 0.07% ) | 1 M $ | 29/04/2024 |
| 17/03/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Michael Kelliher active positions
| Companies | Position | Start |
|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Director/Board Member | 31/08/2023 |
| ARDELYX, INC. | Corporate Officer/Principal | 24/03/2024 |
Former positions of Michael Kelliher
| Companies | Position | End |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Training of Michael Kelliher
| University College Cork | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Michael Kelliher
